2.2825
過往表現並非未來業績的可靠指標. 所示股價僅供參考，可能與實時市價存在差異。
交易 HUTCHMED China Ltd - HCM 差價合約
HUTCHMED (China) Ltd (LSE: HCM) is a biopharmaceutical company focused on the discovery, development, and commercialisation of targeted therapies and immunotherapies for cancer and autoimmune diseases. With a strong R&D pipeline and operations across China and the US, HUTCHMED is advancing innovative treatments for global markets. Its integrated approach, from research to commercialisation, positions it as a key player in Asia’s growing biotech industry.最新股票文章
收息股：股息率分布、選股風險框架與高息ETF配置分析
2026年港股收息股與高息ETF的股息率結構、派息可持續性風險、估值環境及行業分散配置邏輯，涵蓋銀行股、REITs、公用事業及能源板塊的風險收益特徵分析
08:35, 27 3月 2026
平頭哥分拆上市分析：阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市，摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度，解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026
評級和評論
評級和評論
